John Hood, Ph.D


John Hood is a 20 year veteran of the biopharmaceutical industry who has participated in the launch of 3 San Diego biotech companies. Most
recently, Dr. Hood was the Founder and Chief Executive Officer of Impact Biomedicines, a company acquired by Celgene in 2018 in a transaction
valued at up to $7 billion. Prior to founding Impact, Dr. Hood was the Co-Founder and Chief Scientific Officer of Samumed, a pharmaceutical
company focused on advancing regenerative medicine and oncology therapies. Prior to that, Dr. Hood was Director of Research and Co-inventor of
fedratinib at TargeGen, Inc., (subsequently acquired by Sanofi SA), where he led a team identifying small molecule kinase inhibitors for the
treatment of eye diseases and cancer. He is an inventor on 100+ patents and author on 50+ scientific articles. Dr. Hood obtained a Ph.D. in
medical science and B.S. in biochemistry from Texas A&M University.

Michael S. Egan


Mr. Egan has spent over 35 years working in the travel industry. He started at Alamo Rent A Car, Inc. in 1973, became an owner in 1979, and became chairman and majority owner from 1986 to 1996 when he sold the company to AutoNation. In 2000, AutoNation spun off the car rental division and he was named chairman and served in that position until 2003. Since 1996, Mr.Egan has served as the controlling investor of Dancing Bear Investments, Inc., a privately held investment company. Prior to his many business successes, Mr. Egan held various administration positions at Yale University and taught at the University of Massachusetts at Amherst. He is a graduate of the Cornell University School of Hotel Administration . Throughout his career, he has been presented with many honors and awards, including the prestigious Horatio Alger Distinguished American Award in 1997.

Elena Dneprovskaia, Ph.D.


Dr. Dneprovskaia joined Actavalon in 2015 to lead the company’s drug discovery and development programs. She has over 15 years of experience in medicinal chemistry and chemical biology with a strong focus on oncology. Prior to joining Actavalon in 2015, Elena was a Co-Founder and Chief Scientific Officer of Ailuros Biosciences, LLC, a privately held drug discovery company. Previously, she held positions of increasing responsibility in Research and Development at Trega Biosciences, Inc., Lion Bioscience, GmbH., and TargeGen, Inc., where she worked on the development of novel investigational drugs for oncology, ocular, metabolic and cardiovascular diseases and obesity. Dr. Dneprovskaia graduated from Higher Chemical College of the Russian Academy of Sciences in Moscow, Russia and received her Ph.D. in organic chemistry from Iowa State University.